Valuation: Delcath Systems, Inc.

Market Cap 59Cr 51Cr 48Cr 44Cr 83Cr 5.67TCr 84Cr 568.02Cr 221.76Cr 2.84TCr 222.89Cr 218.06Cr 9.46TCr P/E 2026 *
-114x
P/E 2027 * -214x
Enterprise Value 59Cr 51Cr 48Cr 44Cr 83Cr 5.67TCr 84Cr 568.02Cr 221.76Cr 2.84TCr 222.89Cr 218.06Cr 9.46TCr EV / Sales 2026 *
5.59x
EV / Sales 2027 * 4.5x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-0.15%+7.15%-27.16% 2.02TCr
-0.67%+1.97%+5.49%+0.89% 1.76TCr
+1.71%+9.78%-57.07%-42.73% 609.29Cr
-1.53%+1.93% - - 435.02Cr
+0.05%-0.32%+43.79%+37.61% 205.47Cr
+0.85%+2.94%-2.30%-5.40% 194.26Cr
+3.50%+5.87%-45.86%-54.79% 120.42Cr
+0.54%-3.08%+57.45%+164.29% 88Cr
+0.32%+10.02%+53.20%+445.51% 59Cr
Average +0.49%+5.50%+7.73%+64.78% 609.56Cr
Weighted average by Cap. -0.27%+1.71%+0.10%-7.59%

Financials

2026 *2027 *
Net sales 11Cr 9.21Cr 8.63Cr 7.87Cr 15Cr 1.01TCr 15Cr 101.62Cr 40Cr 507.42Cr 40Cr 39Cr 1.69TCr 13Cr 11Cr 11Cr 9.78Cr 18Cr 1.26TCr 19Cr 126.28Cr 49Cr 630.54Cr 50Cr 48Cr 2.1TCr
Net income -57.21L -49.59L -46.49L -42.39L -79.76L -55Cr -81.04L -5.47Cr -2.14Cr -27Cr -2.15Cr -2.1Cr -91Cr -33.88L -29.37L -27.53L -25.1L -47.23L -32Cr -47.99L -3.24Cr -1.27Cr -16Cr -1.27Cr -1.24Cr -54Cr
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-